

## Special Issue

# Immunotherapy for Multiple Myeloma

### Message from the Guest Editors

Multiple myeloma (MM) is a genetically heterogeneous disease that remains mostly incurable, with a small group of patients achieving long-term disease remission. In recent decades, we have witnessed unprecedented progress in the diagnostics and treatment of MM, particularly the advent of immunotherapeutic technologies such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. Currently, CAR-T therapy is approved for relapsed refractory MM, with several ongoing studies investigating its application in earlier lines of therapy including an upfront setting. Despite the impressive response in heavily pre-treated patients, we are now faced with several challenges including access to therapies, requirements for specialized setup for production and administration of CAR-T, management of toxicities, lack of predictive biomarkers and refractory disease. There is a pressing need for clinical and translational research addressing these concerns. This Special Issue reflects the recent developments in immunotherapy, working toward transforming myeloma into a curable disease.

---

### Guest Editors

Dr. Meera Mohan

Medical College of Wisconsin, Milwaukee, WI 53226, USA

Dr. Carolina D. Schinke

Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR 72205, USA

---

### Deadline for manuscript submissions

closed (15 July 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/132336](https://mdpi.com/si/132336)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)